True Vision MN’s DexCom DXCM Stock Holding History

True Vision MN’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,425	Closed	-$426K	–	107
2024 Q1	$426K	Buy	3,425 +131	+4%	+$16.5K	0.3%	66
2023 Q4	$409K	Buy	+3,294	New	+$337K	0.33%	70

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

True Vision MN's DXCM Position: Q2 2024 in Review

True Vision MN sold out of DexCom (DXCM) in Q2 2024, closing a stake of 3,425 shares — an estimated $426K sold.

True Vision MN first reported a position in DXCM in Q4 2023 and held it in 2 quarters. The position peaked at $426K in Q1 2024. 999 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

True Vision MN reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
True Vision MN sold 3,425 DexCom shares in Q2 2024, an estimated $426K.
True Vision MN first reported a position in DexCom in Q4 2023 and held it in 2 quarters.
True Vision MN's DexCom position peaked at $426K in Q1 2024.
999 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on True Vision MN's 13F filing for Q2 2024, filed 12 Aug 2024.